Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

Fedratinib (Inrebic) is available on the NHS. It is a possible treatment for disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential ...